Bennett Jianqing 4

What Happened

• Bennett Jianqing, Senior Vice President, Waters Advanced Diagnostics, received two equity awards on February 25, 2026: 986 restricted stock units (RSUs) and a derivative equity grant covering 4,826 shares. Both grants show an acquisition price of $0.00 (i.e., they were issued as compensation, not bought).
• Total reported shares/rights: 986 RSUs + 4,826 derivative shares. Reported dollar value at grant was $0.00. These are compensation awards (not open‑market purchases or sales).

Key Details

• Transaction date: 2026-02-25; Form 4 filed: 2026-02-27 (timely).
• Price: $0.00 for both grants (compensation awards).
• Vesting: Both awards vest in four equal annual installments with the first vesting on February 25, 2027, subject to continued service.
  • RSUs (986): convert 1-for-1 into common stock upon each vesting (Footnote F1).
  • Derivative (4,826): represents an equity grant whose underlying shares will vest/become exercisable in four equal annual installments beginning Feb 25, 2027 (Footnote F2).
• Shares owned after transaction: not provided in the information supplied.
• Filing status: No late filing indicated; appears timely (filed two days after the transaction).

Context

• These entries are compensation grants (awards), not purchases or sales — common for employee retention and incentive programs and do not indicate immediate buying/selling in the market.
• The derivative grant is a time‑based vesting award (options/rights) — it must vest before converting to or allowing purchase of shares; there’s no indication of a cashless exercise or immediate sale.